Effect of Modified Erchentang on VEGF,VEGFR2,IL-4,ET-1 in Chronic Obstructive Pulmonary Disease Rats
10.13422/j.cnki.syfjx.20192336
- VernacularTitle: 二陈汤加味对慢性阻塞性肺疾病大鼠VEGF，VEGFR2，IL-4，ET-1的影响
- Author:
Wen-ying XIE
1
;
Jun-yue WANG
1
;
Yong-sheng BAO
1
;
Li-zhi SHANG
1
;
Jin-jing LI
1
;
Ke WU
1
;
Liang-zhi ZHANG
1
;
Liang LI
1
;
Xiao-yan WANG
1
;
Qian-hong SONG
1
Author Information
1. Henan University of Traditional Chinese Medicine, Zhengzhou 450046, China
- Publication Type:Research Article
- Keywords:
chronic obstructive pulmonary disease;
interleukin-4;
endothelin-1;
vascular endothelial growth factor(VEGF);
vascular endothelial growth factor receptor 2(VEGFR2)
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2019;25(23):48-55
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To observe the effects of Erchen on vascular endothelial growth factor (VEGF) and its receptor R2 (VEGFR2), interleukin (IL)-4 and endothelin-1 (ET-1) in rats with chronic obstructive pulmonary disease (COPD). Method: The 50 SD rats were randomly divided into 5 groups, 10 rats in each group, which were normal group, model group, Erchentang low, medium and high dose group (10, 20, 40 g · kg-1 · d-1). COPD rat model was established by smoking combined with lipopolysaccharide (LPS) intratracheal drip. After successful modeling, the treatment group was given intragastric administration, and the normal group and the model group were given intragastric distilled water of equal volume. The pathological changes of pulmonary vessels in rats were observed by light microscopy, and the thickness of pulmonary vascular wall was measured. The concentration of IL-4 in rat serum, bronchoalveolar lavage fluid (BALF) and lung homogenate was measured by enzyme-linked immunosorbent assay (ELISA). Real-time fluorescence quantitative polymerase chain reaction (Real-time PCR) was used to detect the expression of ET-1 and immunohistochemistry was used to detect the expression of VEGF,VEGFR2 and ET-1 in lung tissue. Result: Compared with normal group, the concentration of IL-4 in serum, BALF and lung homogenate of model group rats decreased significantly (P<0.05).Compared with model group, the concentration of IL-4 in low, medium and high dose Erchentang group increased in varying degrees (P<0.05). Compared with normal group, the expression of ET-1 in lung tissue of model group was significantly increased (P<0.05).C ompared with model group, the expression of ET-1 in lung tissue of low, medium and high dose Erchentang group was significantly decreased (P<0.05). Compared with normal group, the expression of VEGF, VEGFR2, ET-1 protein in the lung tissue of model group increased (P<0.05). Compared with model group, the expression of VEGF, VEGFR2 and ET-1 protein in the low, medium and high dose Erchentang group decreased (P<0.05). Conclusion: Modified Erchentang can alleviate the process of pulmonary inflammation and pulmonary vascular remodeling in COPD rats, and slow down the progress of COPD and its complications by increasing the content of IL-4, inhibiting the expression of VEGF, VEGFR2, ET-1.
